PDE3A and early-onset autosomal dominant Alzheimer disease: Although there are a limited number of studies, antidepressant [105] and anxiolytic [106] effects have also been observed with cilostazol, a PDE3A inhibitor that has been shown to reduce the decline of cognitive function in patients with Alzheimer’s disease [107].